Year,Therapeutic Name,Eventual Brand Name,NDC Code,"Active Pharmaceutical Ingredient","Gene Delivery System",Targeting Strategy,Delivery Method,NCT ID,Study URL,Study Type,Phase,Trial Status,clinical trial purpose,Therapeutic Purpose,Disease Studied by Clinical Trial,DIsease Targeted by Intervention,Disease Type ,Reason for Termination,Clinical Trial Start Date,Clinical Trial End Date,"Clinical Trial Duration
(Months)",Clinical Trial Size,Enrolled type,Row in the US Polulation sheet that corresponds to the year,Column in the US Population sheet that correspoinds to the age group,Address in the US Population sheet that corresponds to the year and age group,Sex,Age,,Target Population Size,Estimated Disease Prevalence,Estimated Population Affected by Disease,Target Population Indicator,Uptake Propensity,Estimated Potential Impact,Population Multiplier using Age/Sex,Population Impacted,Entity,Entity Type,Entity Employee Count,Entity Size,Entity Research Status,Sponsor,Sponsor Type,Sponsor Class,Collaborators,Manufacturer,Treatment Cost
2024,2024-2025 formula,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06633835,https://clinicaltrials.gov/study/NCT06633835,Interventional,Phase 4,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,9/20/24,12/31/24,3.4,660,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,79.15%,"197,213,032",0.773329128,"4,820,761",Novavax,INDUSTRY,"1,543",Small Pharma,FALSE,Novavax,SPONSOR,INDUSTRY,"""University of Utah""",BioNTech SE,$136.75 
2024,acne mRNA vaccine (ORI-001),N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06316297,https://clinicaltrials.gov/study/NCT06316297,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Acne,Acne,Dermatological,N/A,4/5/24,12/22/27,45.2,386,ESTIMATED,7,4,'1a.1. US Population'!$D$7,ALL,ADULT,Acne,"201,452,958",4.71%,"9,478,887",Common,100.00%,"9,478,887",0.62527118,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2021,ARCT-021,LUNAR-COV19,N/A,self-amplifying RNA,LNP,Untargeted,in-vivo,NCT05037097,https://clinicaltrials.gov/study/NCT05037097,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,8/30/21,12/19/23,28,72,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2021,ARCT-021,LUNAR-COV19,N/A,self-amplifying RNA,LNP,Untargeted,in-vivo,NCT04668339,https://clinicaltrials.gov/study/NCT04668339,Interventional,Phase 2,Terminated,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.,1/7/21,3/1/22,13.9,581,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2021,ARCT-154,KOSTAIVE,N/A,self-amplifying RNA,unclear,Untargeted,in-vivo,NCT05037097,https://clinicaltrials.gov/study/NCT05037097,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,8/30/21,12/19/23,28,72,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2021,ARCT-165,N/A,N/A,self-amplifying RNA,unclear,Untargeted,in-vivo,NCT05037097,https://clinicaltrials.gov/study/NCT05037097,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,8/30/21,12/19/23,28,72,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2024,ARCT-810,LUNAR-OTC,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06488313,https://clinicaltrials.gov/study/NCT06488313,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Ornithine Transcarbamylase Deficiency,Ornithine Transcarbamylase Deficiency,Genetic/Inherited Metabolic,N/A,6/10/24,6/1/26,24,9,ESTIMATED,7,8,'1a.1. US Population'!$H$7,ALL,"CHILD, ADULT, OLDER_ADULT",Ornithine Transcarbamylase Deficiency,"322,184,940",0.00%,"7,081",Rare,100.00%,"7,081",1,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2020,ARCT-810,LUNAR-OTC,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04442347,https://clinicaltrials.gov/study/NCT04442347,Interventional,Phase 1,Completed,TREATMENT,TREATMENT,Ornithine Transcarbamylase Deficiency,Ornithine Transcarbamylase Deficiency,Genetic/Inherited Metabolic,N/A,11/3/20,8/30/23,34.3,16,ACTUAL,11,7,'1a.1. US Population'!$G$11,ALL,"ADULT, OLDER_ADULT",Ornithine Transcarbamylase Deficiency,"249,154,999",0.00%,"5,476",Ultra-Rare,100.00%,"5,476",0.773329128,0,"Arcturus Therapeutics, Inc.",INDUSTRY,180,Small Pharma,TRUE,"Arcturus Therapeutics, Inc.",SPONSOR,INDUSTRY,N/A,"Arcturus Therapeutics, Inc.",N/A
2023,ARTEMIS-C (AZD9838 and AZD6563),N/A,N/A,messenger RNA,VLP,Untargeted,in-vivo,NCT06147063,https://clinicaltrials.gov/study/NCT06147063,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"COVID-19, SARS-CoV-2 Infection",COVID-19,Infectious,N/A,11/27/23,4/30/24,5.2,243,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,0,AstraZeneca,INDUSTRY,"89,900",Big Pharma,TRUE,AstraZeneca,SPONSOR,INDUSTRY,N/A,AstraZeneca,N/A
2022,BG505 MD39.3 gp151 CD4KO mRNA,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05217641,https://clinicaltrials.gov/study/NCT05217641,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,HIV,HIV,Infectious,N/A,2/11/22,7/17/23,17.4,108,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,83.65%,"168,513,018",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""National Institutes of Health (NIH)"", ""Department of Health and Human Services""","ModernaTX, Inc.",N/A
2022,BG505 MD39.3 gp151 mRNA,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05217641,https://clinicaltrials.gov/study/NCT05217641,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,HIV,HIV,Infectious,N/A,2/11/22,7/17/23,17.4,108,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,83.65%,"168,513,018",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""National Institutes of Health (NIH)"", ""Department of Health and Human Services""","ModernaTX, Inc.",N/A
2022,BG505 MD39.3 mRNA,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05217641,https://clinicaltrials.gov/study/NCT05217641,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,HIV,HIV,Infectious,N/A,2/11/22,7/17/23,17.4,108,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,83.65%,"168,513,018",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""National Institutes of Health (NIH)"", ""Department of Health and Human Services""","ModernaTX, Inc.",N/A
2017,BI 1361849 (formerly CV9202),N/A,N/A,messenger RNA,Other,Active,in-vivo,NCT03164772,https://clinicaltrials.gov/study/NCT03164772,Interventional,Phase 2,Completed,TREATMENT,TREATMENT,"Metastatic Non-small Cell Lung Cancer, NSCLC",Lung Cancer,Cancer,N/A,12/20/17,10/29/21,47,61,ACTUAL,14,7,'1a.1. US Population'!$G$14,ALL,"ADULT, OLDER_ADULT",Lung Cancer,"250,825,102",0.20%,"489,534",Common,100.00%,"489,534",0.77283439,0,Ludwig Institute for Cancer Research,OTHER,non-industry,Non-Industry,FALSE,Ludwig Institute for Cancer Research,SPONSOR,OTHER,"""Cancer Research Institute (CRI)"", ""Boehringer Ingelheim"", ""MedImmune LLC"", ""CureVac"", ""PharmaJet, Inc.""",CureVac and Boehringer Ingelheim.,N/A
2020,biological: mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04405076,https://clinicaltrials.gov/study/NCT04405076,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/29/20,10/28/21,17.2,660,ACTUAL,11,7,'1a.1. US Population'!$G$11,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",1.44%,"3,584,405",Common,67.69%,"168,658,393",0.773329128,"856,186","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",$141.80 
2021,biological/vaccine: bnt162b2 10mcg,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04816643,https://clinicaltrials.gov/study/NCT04816643,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,3/24/21,10/4/23,30.8,11837,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"66,695,800",BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,"""Pfizer""",BioNTech SE,$136.75 
2021,biological/vaccine: bnt162b2 3mcg,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04816643,https://clinicaltrials.gov/study/NCT04816643,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,3/24/21,10/4/23,30.8,11837,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"66,695,800",BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,"""Pfizer""",BioNTech SE,$136.75 
2023,bivalent bnt162b2 (original/omi ba.4/ba.5),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05886777,https://clinicaltrials.gov/study/NCT05886777,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Healthy Participants,COVID-19,Infectious,N/A,6/5/23,1/1/24,7,1084,ACTUAL,8,5,'1a.1. US Population'!$E$8,ALL,OLDER_ADULT,COVID-19,"47,702,041",2.61%,"1,245,103",Common,83.19%,"39,682,064",0.148057948,"922,960",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2022,bivalent bnt162b2 mrna original/omicron ba.4-5 vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05970887,https://clinicaltrials.gov/study/NCT05970887,Interventional,Phase 4,Completed,BASIC_SCIENCE,PREVENTION,"Immune Response, Safety",COVID-19,Infectious,N/A,10/12/22,12/15/22,2.1,154,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",Catholic Kwandong University,OTHER,non-industry,Non-Industry,FALSE,Catholic Kwandong University,PRINCIPAL_INVESTIGATOR,OTHER,"""Korea University Guro Hospital""",BioNTech SE,$136.75 
2019,bnt112,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT04382898,https://clinicaltrials.gov/study/NCT04382898,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,Prostate Cancer,Prostate Cancer,Cancer,Sponsor decision,12/19/19,1/23/24,49.9,75,ACTUAL,12,13,'1a.1. US Population'!$M$12,MALE,"ADULT, OLDER_ADULT",Prostate Cancer,"123,962,067",2.60%,"3,222,690",Common,100.00%,"3,222,690",0.384754379,0,BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,N/A,BioNTech SE,N/A
2021,bnt113,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT04534205,https://clinicaltrials.gov/study/NCT04534205,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,"Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer",Head and Neck Cancer,Cancer,N/A,1/7/21,5/1/28,89,285,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",Head and Neck Cancer,"249,154,999",0.22%,"541,218",Common,100.00%,"541,218",0.773329128,0,BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,N/A,BioNTech SE,N/A
2022,bnt141,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT04683939,https://clinicaltrials.gov/study/NCT04683939,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,"Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer",Cancer,Cancer,Sponsor decision,1/18/22,7/24/23,18.4,13,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Cancer,"249,154,999",6.87%,"17,125,887",Common,100.00%,"17,125,887",0.773329128,0,BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,N/A,BioNTech SE,N/A
2022,bnt162b2 (b.1.1.529),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2022,bnt162b2 (b.1.351),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2024,bnt162b2 (omi xbb.1.5),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237049,https://clinicaltrials.gov/study/NCT06237049,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Influenza, Human, SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,1/31/24,9/13/24,7.5,645,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,79.15%,"197,213,032",0.773329128,"4,820,761",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2024,bnt162b2 (omi xbb.1.5)/riv,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237049,https://clinicaltrials.gov/study/NCT06237049,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Influenza, Human, SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,1/31/24,9/13/24,7.5,645,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,79.15%,"197,213,032",0.773329128,"4,820,761",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2021,bnt162b2 20mcg,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04816643,https://clinicaltrials.gov/study/NCT04816643,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,3/24/21,10/4/23,30.8,11837,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"66,695,800",BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,"""Pfizer""",BioNTech SE,$136.75 
2021,bnt162b2 30mcg,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04816643,https://clinicaltrials.gov/study/NCT04816643,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"SARS-CoV-2 Infection, COVID-19",COVID-19,Infectious,N/A,3/24/21,10/4/23,30.8,11837,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"66,695,800",BioNTech SE,INDUSTRY,"6,133",Small Pharma,TRUE,BioNTech SE,SPONSOR,INDUSTRY,"""Pfizer""",BioNTech SE,$136.75 
2021,bnt162b2 ba.4/5 bivalent,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04848584,https://clinicaltrials.gov/study/NCT04848584,Observational,Observational,Recruiting,,PREVENTION,COVID-19,COVID-19,Infectious,N/A,5/15/21,6/15/25,49.7,999,ESTIMATED,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2022,bnt162b2 bivalent (wildtype and omicron ba.1),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2022,bnt162b2 bivalent (wildtype and omicron ba.4/ba.5),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2021,bnt162b2 vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05016622,https://clinicaltrials.gov/study/NCT05016622,Interventional,Phase 2,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,"Due to decreased level of engagement and available funding, PI determined it appropriate to close the study prior to visit occurring. IRB approved.",8/10/21,4/20/22,8.4,106,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Montefiore Medical Center,OTHER,non-industry,Non-Industry,FALSE,Montefiore Medical Center,SPONSOR,OTHER,"""Albert Einstein College of Medicine"", ""National Cancer Institute (NCI)"", ""The Leukemia and Lymphoma Society""",BioNTech SE,$136.75 
2024,ch505 tf mrna-gp160,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06557785,https://clinicaltrials.gov/study/NCT06557785,Interventional,Phase 1,Not Yet Recruiting,PREVENTION,PREVENTION,HIV Infections,HIV,Infectious,N/A,11/7/24,1/3/26,14.1,48,ESTIMATED,7,4,'1a.1. US Population'!$D$7,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,79.15%,"159,455,555",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""National Institutes of Health (NIH)"", ""Department of Health and Human Services""",Duke CHAVD,N/A
2024,ch505m5 n197d mrna-gp160,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06557785,https://clinicaltrials.gov/study/NCT06557785,Interventional,Phase 1,Not Yet Recruiting,PREVENTION,PREVENTION,HIV Infections,HIV,Infectious,N/A,11/7/24,1/3/26,14.1,48,ESTIMATED,7,4,'1a.1. US Population'!$D$7,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,79.15%,"159,455,555",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""National Institutes of Health (NIH)"", ""Department of Health and Human Services""",Duke CHAVD,N/A
2024,cominarty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06587503,https://clinicaltrials.gov/study/NCT06587503,Interventional,Phase 4,Not Yet Recruiting,PREVENTION,PREVENTION,"Ebola Virus Disease, COVID-19",COVID-19,Infectious,N/A,10/1/24,12/1/24,2,72,ESTIMATED,7,4,'1a.1. US Population'!$D$7,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,79.15%,"159,455,555",0.62527118,"3,897,801",University of Birmingham,OTHER,non-industry,Non-Industry,FALSE,University of Birmingham,SPONSOR,OTHER,"""Project San Francisco"", ""Rwanda Biomedical Centre"", ""Merck Sharp & Dohme LLC""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,0069-2432,messenger RNA,LNP,Untargeted,in-vivo,NCT04780659,https://clinicaltrials.gov/study/NCT04780659,Interventional,Phase 4,Active Not Recruiting,PREVENTION,PREVENTION,Covid19,COVID-19,Infectious,N/A,2/23/21,3/31/24,37.7,540,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Karolinska University Hospital,OTHER,non-industry,Non-Industry,FALSE,Karolinska University Hospital,PRINCIPAL_INVESTIGATOR,OTHER,"""Karolinska Institutet""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05057169,https://clinicaltrials.gov/study/NCT05057169,Interventional,Phase 4,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19 Vaccination,COVID-19,Infectious,N/A,11/18/21,12/31/24,38,400,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",The University of Hong Kong,OTHER,non-industry,Non-Industry,FALSE,The University of Hong Kong,SPONSOR,OTHER,N/A,BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05057182,https://clinicaltrials.gov/study/NCT05057182,Interventional,Phase 4,Active Not Recruiting,PREVENTION,PREVENTION,COVID 19 Vaccine,COVID-19,Infectious,N/A,10/18/21,3/31/24,29.8,300,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",The University of Hong Kong,OTHER,non-industry,Non-Industry,FALSE,The University of Hong Kong,SPONSOR,OTHER,N/A,BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,0069-2432,messenger RNA,LNP,Untargeted,in-vivo,NCT04775069,https://clinicaltrials.gov/study/NCT04775069,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,Chronic Liver Disease,COVID-19,Infectious,N/A,5/21/21,9/30/23,28.7,232,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Humanity & Health Medical Group Limited,OTHER,non-industry,Non-Industry,FALSE,Humanity & Health Medical Group Limited,SPONSOR,OTHER,N/A,BioNTech SE,$136.75 
2022,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05168709,https://clinicaltrials.gov/study/NCT05168709,Interventional,Phase 4,Completed,BASIC_SCIENCE,PREVENTION,"COVID-19, Vaccine Reaction, Immunization; Infection",COVID-19,Infectious,N/A,1/20/22,9/29/22,8.4,51,ACTUAL,9,3,'1a.1. US Population'!$C$9,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"22,345,520",Murdoch Childrens Research Institute,OTHER,non-industry,Non-Industry,FALSE,Murdoch Childrens Research Institute,SPONSOR,OTHER,N/A,BioNTech SE,$136.75 
2022,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05343871,https://clinicaltrials.gov/study/NCT05343871,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,7/5/22,7/28/23,12.9,2354,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,83.65%,"168,513,018",0.62527118,"61,640,075",Albert B. Sabin Vaccine Institute,OTHER,non-industry,Non-Industry,FALSE,Albert B. Sabin Vaccine Institute,SPONSOR,OTHER,"""Aga Khan University"", ""Oswaldo Cruz Foundation"", ""Stanford University""",BioNTech SE,$136.75 
2022,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05212610,https://clinicaltrials.gov/study/NCT05212610,Interventional,Phase 4,Recruiting,TREATMENT,PREVENTION,"COVID-19, Corona Virus Infection",COVID-19,Infectious,N/A,3/21/22,12/30/24,33.8,200,ESTIMATED,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",University of Michigan,OTHER,non-industry,Non-Industry,FALSE,University of Michigan,PRINCIPAL_INVESTIGATOR,OTHER,"""The Wallace Foundation""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05077254,https://clinicaltrials.gov/study/NCT05077254,Interventional,Phase 2,Active Not Recruiting,TREATMENT,PREVENTION,"Kidney Transplant Recipients, Liver Transplant Recipients",COVID-19,Infectious,N/A,12/6/21,2/28/24,27.1,400,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""PPD DEVELOPMENT, LP"", ""Johns Hopkins University""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04889209,https://clinicaltrials.gov/study/NCT04889209,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,5/28/21,6/16/23,25,867,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04969263,https://clinicaltrials.gov/study/NCT04969263,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Kidney Transplant Recipients,COVID-19,Infectious,N/A,8/10/21,11/10/22,15.2,81,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""PPD DEVELOPMENT, LP""",BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05000216,https://clinicaltrials.gov/study/NCT05000216,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)",COVID-19,Infectious,N/A,8/13/21,6/22/23,22.6,257,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""Autoimmunity Centers of Excellence"", ""Rho Federal Systems Division, Inc.""",BioNTech SE,$136.75 
2022,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"76,235,826",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2021,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05020145,https://clinicaltrials.gov/study/NCT05020145,Observational,Observational,Completed,,PREVENTION,"Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2, SARS-COV-2 Infection, Breakthrough Infection",COVID-19,Infectious,N/A,8/25/21,12/17/21,3.8,1277747,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2023,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05765578,https://clinicaltrials.gov/study/NCT05765578,Observational,Observational,Completed,,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/8/23,6/17/24,15.6,1713,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"4,820,761","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2023,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05858450,https://clinicaltrials.gov/study/NCT05858450,Observational,Observational,Completed,,PREVENTION,"Influenza, Human, COVID-19",COVID-19,Infectious,N/A,5/5/23,5/12/23,0.2,3442996,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"4,820,761",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2023,comirnaty,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05876377,https://clinicaltrials.gov/study/NCT05876377,Observational,Observational,Recruiting,,PREVENTION,"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome",COVID-19,Infectious,N/A,10/23/23,10/31/24,12.5,999,ESTIMATED,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,"6,233,777",Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2021,comirnaty - biontech manufacturing gmbh,Comirnaty,0069-2432,messenger RNA,LNP,Untargeted,in-vivo,NCT04760132,https://clinicaltrials.gov/study/NCT04760132,Interventional,Phase 4,Completed,OTHER,PREVENTION,SARS-CoV Infection,COVID-19,Infectious,N/A,2/8/21,12/31/23,35.2,7600,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916","Rigshospitalet, Denmark",OTHER,non-industry,Non-Industry,FALSE,"Jens D Lundgren, MD",SPONSOR_INVESTIGATOR,OTHER,"""Ministry of the Interior and Health, Denmark""",BioNTech SE,$136.75 
2021,comirnaty omicron xbb.1.5,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""",BioNTech SE,$136.75 
2021,comirnaty original/omicron ba.1,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""",BioNTech SE,$136.75 
2021,comirnaty original/omicron ba.4-5,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""",BioNTech SE,$136.75 
2021,comirnaty®,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04792567,https://clinicaltrials.gov/study/NCT04792567,Interventional,Phase 4,Completed,TREATMENT,PREVENTION,Secondary Progressive Multiple Sclerosis,COVID-19,Infectious,N/A,4/19/21,9/6/21,4.7,41,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Novartis,INDUSTRY,"76,057",Big Pharma,FALSE,Novartis Pharmaceuticals,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2024,comirnaty®,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06672055,https://clinicaltrials.gov/study/NCT06672055,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,"SARS-CoV2, COVID-19",COVID-19,Infectious,N/A,10/8/24,1/1/26,15,10000,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,100.00%,"6,503,362",0.773329128,"4,820,761",Vaxart,INDUSTRY,109,Small Pharma,FALSE,Vaxart,SPONSOR,INDUSTRY,N/A,BioNTech SE,$136.75 
2021,core-g28v2 60mer mrna vaccine,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05001373,https://clinicaltrials.gov/study/NCT05001373,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Hiv,HIV,Infectious,N/A,11/12/21,6/20/23,19.5,56,ESTIMATED,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,67.69%,"136,367,853",0.62527118,0,International AIDS Vaccine Initiative,NETWORK,non-industry,Non-Industry,TRUE,International AIDS Vaccine Initiative,SPONSOR,NETWORK,"""ModernaTX, Inc."", ""George Washington University"", ""Fred Hutchinson Cancer Center"", ""Emory University"", ""UT Health San Antonio""","ModernaTX, Inc.",N/A
2021,CoV2 SAM,N/A,N/A,self-amplifying RNA,LNP,Untargeted,in-vivo,NCT04758962,https://clinicaltrials.gov/study/NCT04758962,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,2/15/21,6/4/21,3.6,40,ACTUAL,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,67.69%,"136,367,853",0.62527118,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2021,covid 19 booster dose,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05028374,https://clinicaltrials.gov/study/NCT05028374,Interventional,Phase 2,Completed,TREATMENT,TREATMENT,"Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia",COVID-19,Infectious,N/A,8/17/21,11/2/21,2.6,119,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,100.00%,"6,503,362",0.773329128,"149,371,035",Barbara Ann Karmanos Cancer Institute,OTHER,non-industry,Non-Industry,FALSE,Barbara Ann Karmanos Cancer Institute,PRINCIPAL_INVESTIGATOR,OTHER,N/A,"ModernaTX, Inc.",$141.80 
2021,covid-19 mrna vaccine moderna (1 dose),Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05047718,https://clinicaltrials.gov/study/NCT05047718,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,Covid19,COVID-19,Infectious,N/A,10/5/21,8/29/22,10.9,54,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Centre Hospitalier Universitaire de Saint Etienne,OTHER,non-industry,Non-Industry,FALSE,Centre Hospitalier Universitaire de Saint Etienne,SPONSOR,OTHER,"""Sanofi Pasteur, a Sanofi Company"", ""Bioster, a.s.""","ModernaTX, Inc.",$141.80 
2021,covid-19 mrna vaccine moderna (2 doses),Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05047718,https://clinicaltrials.gov/study/NCT05047718,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,Covid19,COVID-19,Infectious,N/A,10/5/21,8/29/22,10.9,54,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Centre Hospitalier Universitaire de Saint Etienne,OTHER,non-industry,Non-Industry,FALSE,Centre Hospitalier Universitaire de Saint Etienne,SPONSOR,OTHER,"""Sanofi Pasteur, a Sanofi Company"", ""Bioster, a.s.""","ModernaTX, Inc.",$141.80 
2021,covid-19 vaccine moderna dispersion for injection - moderna biotech,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04760132,https://clinicaltrials.gov/study/NCT04760132,Interventional,Phase 4,Completed,OTHER,PREVENTION,SARS-CoV Infection,COVID-19,Infectious,N/A,2/8/21,12/31/23,35.2,7600,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","Rigshospitalet, Denmark",OTHER,non-industry,Non-Industry,FALSE,"Jens D Lundgren, MD",SPONSOR_INVESTIGATOR,OTHER,"""Ministry of the Interior and Health, Denmark""","ModernaTX, Inc.",$141.80 
2021,covid-19 vaccine pfizer (1 dose),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05047718,https://clinicaltrials.gov/study/NCT05047718,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,Covid19,COVID-19,Infectious,N/A,10/5/21,8/29/22,10.9,54,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Centre Hospitalier Universitaire de Saint Etienne,OTHER,non-industry,Non-Industry,FALSE,Centre Hospitalier Universitaire de Saint Etienne,SPONSOR,OTHER,"""Sanofi Pasteur, a Sanofi Company"", ""Bioster, a.s.""",BioNTech SE,$136.75 
2021,covid-19 vaccine pfizer (2 doses),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05047718,https://clinicaltrials.gov/study/NCT05047718,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,Covid19,COVID-19,Infectious,N/A,10/5/21,8/29/22,10.9,54,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Centre Hospitalier Universitaire de Saint Etienne,OTHER,non-industry,Non-Industry,FALSE,Centre Hospitalier Universitaire de Saint Etienne,SPONSOR,OTHER,"""Sanofi Pasteur, a Sanofi Company"", ""Bioster, a.s.""",BioNTech SE,$136.75 
2014,"CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells",N/A,N/A,messenger RNA,Other,Active,ex-vivo,NCT01995708,https://clinicaltrials.gov/study/NCT01995708,Interventional,Phase 1,Completed,TREATMENT,TREATMENT,Multiple Myeloma,Myeloma,Cancer,N/A,1/31/14,6/20/22,102.1,28,ACTUAL,17,8,'1a.1. US Population'!$H$17,ALL,"CHILD, ADULT, OLDER_ADULT",Myeloma,"318,456,985",0.00%,326,Ultra-Rare,100.00%,326,1,0,Memorial Sloan Kettering Cancer Center,OTHER,non-industry,Non-Industry,TRUE,Memorial Sloan Kettering Cancer Center,SPONSOR,OTHER,N/A,Memorial Sloan Kettering Cancer Center,N/A
2023,dcvc h1 ha mrna vaccine,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05945485,https://clinicaltrials.gov/study/NCT05945485,Interventional,Phase 1,Recruiting,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,10/16/23,5/19/25,19.4,50,ESTIMATED,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,37.00%,"74,537,594",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,Duke Civics Vaccine Center,N/A
2021,eod-gt8 60mer mrna vaccine,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05001373,https://clinicaltrials.gov/study/NCT05001373,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Hiv,HIV,Infectious,N/A,11/12/21,6/20/23,19.5,56,ESTIMATED,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,67.69%,"136,367,853",0.62527118,0,International AIDS Vaccine Initiative,NETWORK,non-industry,Non-Industry,TRUE,International AIDS Vaccine Initiative,SPONSOR,NETWORK,"""ModernaTX, Inc."", ""George Washington University"", ""Fred Hutchinson Cancer Center"", ""Emory University"", ""UT Health San Antonio""","ModernaTX, Inc.",N/A
2024,flu pandemic mrna_dose level 1,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 2,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 3,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 4,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 5,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 6,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,flu pandemic mrna_dose level 7,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06382311,https://clinicaltrials.gov/study/NCT06382311,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/18/24,8/21/24,4.2,1080,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2022,grt-r902,N/A,N/A,self-amplifying RNA,Other,Active,in-vivo,NCT05456165,https://clinicaltrials.gov/study/NCT05456165,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,"Colonic Neoplasms, Colorectal Neoplasms",Colon and rectum cancer,Cancer,terminated due to reprioritization,5/19/22,9/1/22,3.5,1,ACTUAL,9,8,'1a.1. US Population'!$H$9,ALL,"CHILD, ADULT, OLDER_ADULT",Colon and rectum cancer,"322,184,940",0.01%,"22,923",Rare,100.00%,"22,923",1,0,"Gritstone bio, Inc.",INDUSTRY,231,Small Pharma,TRUE,"Gritstone bio, Inc.",SPONSOR,INDUSTRY,N/A,"Gritstone bio, Inc.",N/A
2023,gsk4382276a,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT05823974,https://clinicaltrials.gov/study/NCT05823974,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,2/27/23,7/11/24,16.7,1256,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,"""CureVac""",GlaxoSmithKline,N/A
2024,gsk4382276a,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06431607,https://clinicaltrials.gov/study/NCT06431607,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,5/23/24,7/15/24,1.8,510,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2021,heterologous mrna booster vaccine,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05142319,https://clinicaltrials.gov/study/NCT05142319,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,10/12/21,6/1/23,19.9,326,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Tan Tock Seng Hospital,OTHER,non-industry,Non-Industry,FALSE,Tan Tock Seng Hospital,PRINCIPAL_INVESTIGATOR,OTHER,"""A*Star"", ""KK Women's and Children's Hospital"", ""Duke-NUS Graduate Medical School""","ModernaTX, Inc.",$141.80 
2024,hmpv mrna lnp 1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237296,https://clinicaltrials.gov/study/NCT06237296,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"Respiratory Syncytial Virus, Healthy Volunteers, Metapneumovirus Infection",Respiratory Syncytial Virus,Infectious,N/A,1/23/24,2/18/25,13.1,558,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,79.15%,"197,213,032",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2021,homologous mrna booster vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05142319,https://clinicaltrials.gov/study/NCT05142319,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,10/12/21,6/1/23,19.9,326,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Tan Tock Seng Hospital,OTHER,non-industry,Non-Industry,FALSE,Tan Tock Seng Hospital,PRINCIPAL_INVESTIGATOR,OTHER,"""A*Star"", ""KK Women's and Children's Hospital"", ""Duke-NUS Graduate Medical School""",BioNTech SE,$136.75 
2022,influenza hemagglutinin mrna vaccine,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06118151,https://clinicaltrials.gov/study/NCT06118151,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Influenza Immunization",Influenza,Infectious,N/A,4/11/22,2/17/23,10.4,388,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2016,intralesional mrna 2752,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT02872025,https://clinicaltrials.gov/study/NCT02872025,Interventional,Pre-Clinical,Recruiting,TREATMENT,TREATMENT,"Carcinoma, Intraductal, Noninfiltrating",Breast Cancer,Cancer,N/A,12/12/16,3/31/25,101,68,ESTIMATED,15,19,'1a.1. US Population'!$S$15,FEMALE,"ADULT, OLDER_ADULT",Breast Cancer,"127,700,162",2.98%,"3,810,835",Common,100.00%,"3,810,835",0.395759815,0,"University of California, San Francisco",OTHER,non-industry,Non-Industry,TRUE,Laura Esserman,SPONSOR_INVESTIGATOR,OTHER,"""Merck Sharp & Dohme LLC"", ""ModernaTX, Inc.""","ModernaTX, Inc.",N/A
2023,moderna 2023 updated covid-19 vaccine (xbb.1.5),Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05765578,https://clinicaltrials.gov/study/NCT05765578,Observational,Observational,Completed,,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/8/23,6/17/24,15.6,1713,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"2,540,492","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2023,moderna covid-19 mrna vaccine,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05392075,https://clinicaltrials.gov/study/NCT05392075,Observational,Observational,Completed,,PREVENTION,"COVID-19 Pneumonia, COVID-19",COVID-19,Infectious,N/A,3/15/23,3/15/23,0,100,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"2,540,492",Methodist Health System,OTHER,non-industry,Non-Industry,FALSE,Methodist Health System,SPONSOR,OTHER,N/A,"ModernaTX, Inc.",$141.80 
2023,moderna covid-19 vaccine,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06038617,https://clinicaltrials.gov/study/NCT06038617,Interventional,Phase 4,Recruiting,PREVENTION,PREVENTION,"Fever After Vaccination, Fever, Seizures Fever",COVID-19,Infectious,N/A,10/30/23,9/1/25,22.4,600,ESTIMATED,8,3,'1a.1. US Population'!$C$8,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,46.36%,"33,855,464",0.226670872,"744,645",Duke University,OTHER,non-industry,Non-Industry,FALSE,Duke University,SPONSOR,OTHER,"""Kaiser Permanente"",""Columbia University"", ""Children's Hospital Medical Center, Cincinnati"", ""Centers for Disease Control and Prevention""","ModernaTX, Inc.",$141.80 
2021,moderna covid-19 vaccine (mrna-1273 vaccine),Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04969276,https://clinicaltrials.gov/study/NCT04969276,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Influenza Immunization, Healthy Volunteers",COVID-19,Infectious,N/A,7/16/21,2/8/22,6.9,306,ACTUAL,10,5,'1a.1. US Population'!$E$10,ALL,OLDER_ADULT,COVID-19,"47,702,041",2.61%,"1,245,103",Common,67.69%,"32,290,541",0.148057948,"28,597,874","Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2023,moderna mrna1273.222 booster,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05765578,https://clinicaltrials.gov/study/NCT05765578,Observational,Observational,Completed,,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/8/23,6/17/24,15.6,1713,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"2,540,492","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,moderna vaccine,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04912700,https://clinicaltrials.gov/study/NCT04912700,Observational,Observational,Completed,,PREVENTION,Covid19,COVID-19,Infectious,N/A,6/1/21,6/7/21,0.2,11834,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",William Beaumont Hospitals,OTHER,non-industry,Non-Industry,FALSE,William Beaumont Hospitals,PRINCIPAL_INVESTIGATOR,OTHER,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna covid-19,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05028361,https://clinicaltrials.gov/study/NCT05028361,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,"Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction",COVID-19,Infectious,N/A,10/4/21,3/3/23,17.2,348,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",Duke University,OTHER,non-industry,Non-Industry,FALSE,Duke University,SPONSOR,OTHER,"""CDC"",  ""Johns Hopkins University"", ""Children's Hospital Medical Center, Cincinnati""",BioNTech SE,$136.75 
2021,mrna covid-19,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05028361,https://clinicaltrials.gov/study/NCT05028361,Interventional,Phase 4,Completed,PREVENTION,PREVENTION,"Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction",COVID-19,Infectious,N/A,10/4/21,3/3/23,17.2,348,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"193,153,251",Duke University,OTHER,non-industry,Non-Industry,FALSE,Duke University,SPONSOR,OTHER,"""CDC"",  ""Johns Hopkins University"", ""Children's Hospital Medical Center, Cincinnati""","ModernaTX, Inc.",$141.80 
2020,mrna covid-19 vaccine (pfizer or moderna),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05197621,https://clinicaltrials.gov/study/NCT05197621,Observational,Observational,Recruiting,,PREVENTION,"COVID-19, Pregnancy; Infection",COVID-19,Infectious,N/A,4/13/20,5/5/25,61.6,300,ESTIMATED,11,18,'1a.1. US Population'!$R$11,FEMALE,"CHILD, ADULT",COVID-19,"137,044,846",0.88%,"1,200,865",Common,41.95%,"57,490,313",0.425360807,"1,118,748",Johns Hopkins University,OTHER,non-industry,Non-Industry,FALSE,Johns Hopkins University,SPONSOR,OTHER,"""Integrated Research Center for Fetal Medicine""",BioNTech SE,$136.75 
2020,mrna covid-19 vaccine (pfizer or moderna),Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05197621,https://clinicaltrials.gov/study/NCT05197621,Observational,Observational,Recruiting,,PREVENTION,"COVID-19, Pregnancy; Infection",COVID-19,Infectious,N/A,4/13/20,5/5/25,61.6,300,ESTIMATED,11,18,'1a.1. US Population'!$R$11,FEMALE,"CHILD, ADULT",COVID-19,"137,044,846",0.88%,"1,200,865",Common,41.95%,"57,490,313",0.425360807,"470,935",Johns Hopkins University,OTHER,non-industry,Non-Industry,FALSE,Johns Hopkins University,SPONSOR,OTHER,"""Integrated Research Center for Fetal Medicine""","ModernaTX, Inc.",$141.80 
2022,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05566639,https://clinicaltrials.gov/study/NCT05566639,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,9/14/22,1/5/24,15.9,22510,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827978,https://clinicaltrials.gov/study/NCT05827978,Interventional,Phase 3,Completed,TREATMENT,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,4/17/23,6/24/24,14.5,8422,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05333289,https://clinicaltrials.gov/study/NCT05333289,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,4/6/22,11/22/22,7.7,572,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05868382,https://clinicaltrials.gov/study/NCT05868382,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,5/15/23,12/19/23,7.3,270,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,37.00%,"74,537,594",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05397223,https://clinicaltrials.gov/study/NCT05397223,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus",Influenza,Infectious,N/A,5/24/22,2/21/26,45.6,308,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1010,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05585632,https://clinicaltrials.gov/study/NCT05585632,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza, RSV",Influenza,Infectious,N/A,10/14/22,2/28/24,16.7,392,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010.2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010.3,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010.4,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05868382,https://clinicaltrials.gov/study/NCT05868382,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,5/15/23,12/19/23,7.3,270,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,37.00%,"74,537,594",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1010.6,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05868382,https://clinicaltrials.gov/study/NCT05868382,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,5/15/23,12/19/23,7.3,270,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,37.00%,"74,537,594",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1011.1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1011.2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1012.1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827068,https://clinicaltrials.gov/study/NCT05827068,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,3/27/23,11/20/23,7.9,700,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1018 for h5 only,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05972174,https://clinicaltrials.gov/study/NCT05972174,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,7/10/23,7/16/24,12.4,1504,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1018 for h5 only-cg,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05972174,https://clinicaltrials.gov/study/NCT05972174,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,7/10/23,7/16/24,12.4,1504,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1018 for h5n8,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05972174,https://clinicaltrials.gov/study/NCT05972174,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,7/10/23,7/16/24,12.4,1504,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1018 for h7 only,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05972174,https://clinicaltrials.gov/study/NCT05972174,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,7/10/23,7/16/24,12.4,1504,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1018 for h7n9,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05972174,https://clinicaltrials.gov/study/NCT05972174,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza,Influenza,Infectious,N/A,7/10/23,7/16/24,12.4,1504,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1020,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05333289,https://clinicaltrials.gov/study/NCT05333289,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,4/6/22,11/22/22,7.7,572,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1030,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05333289,https://clinicaltrials.gov/study/NCT05333289,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Seasonal Influenza,Influenza,Infectious,N/A,4/6/22,11/22/22,7.7,572,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1045,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05585632,https://clinicaltrials.gov/study/NCT05585632,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza, RSV",Influenza,Infectious,N/A,10/14/22,2/28/24,16.7,392,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1083,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06097273,https://clinicaltrials.gov/study/NCT06097273,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza",Influenza,Infectious,N/A,10/19/23,5/28/24,7.4,8075,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1083,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827926,https://clinicaltrials.gov/study/NCT05827926,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza",Influenza,Infectious,N/A,4/14/23,12/2/24,19.9,1763,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1083.1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827926,https://clinicaltrials.gov/study/NCT05827926,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza",Influenza,Infectious,N/A,4/14/23,12/2/24,19.9,1763,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1083.2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827926,https://clinicaltrials.gov/study/NCT05827926,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza",Influenza,Infectious,N/A,4/14/23,12/2/24,19.9,1763,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1083.3,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05827926,https://clinicaltrials.gov/study/NCT05827926,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza",Influenza,Infectious,N/A,4/14/23,12/2/24,19.9,1763,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1189,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05164094,https://clinicaltrials.gov/study/NCT05164094,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Epstein-Barr Virus Infection,Epstein-Barr Virus,Infectious,N/A,12/28/21,6/18/25,42.3,422,ESTIMATED,10,6,'1a.1. US Population'!$F$10,ALL,"CHILD, ADULT",Epstein-Barr Virus,"274,482,899",90.00%,"247,034,609",Common,41.95%,"115,145,576",0.851942052,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1189,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05831111,https://clinicaltrials.gov/study/NCT05831111,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Epstein-Barr Virus Infection,Epstein-Barr Virus,Infectious,N/A,4/5/23,2/4/26,34.5,354,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Epstein-Barr Virus,"201,452,958",90.00%,"181,307,662",Common,83.19%,"167,583,377",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1195.1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05831111,https://clinicaltrials.gov/study/NCT05831111,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Epstein-Barr Virus Infection,Epstein-Barr Virus,Infectious,N/A,4/5/23,2/4/26,34.5,354,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Epstein-Barr Virus,"201,452,958",90.00%,"181,307,662",Common,83.19%,"167,583,377",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1195.2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05831111,https://clinicaltrials.gov/study/NCT05831111,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,Epstein-Barr Virus Infection,Epstein-Barr Virus,Infectious,N/A,4/5/23,2/4/26,34.5,354,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Epstein-Barr Virus,"201,452,958",90.00%,"181,307,662",Common,83.19%,"167,583,377",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1230,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05585632,https://clinicaltrials.gov/study/NCT05585632,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza, RSV",Influenza,Infectious,N/A,10/14/22,2/28/24,16.7,392,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04792567,https://clinicaltrials.gov/study/NCT04792567,Interventional,Phase 4,Completed,TREATMENT,PREVENTION,Secondary Progressive Multiple Sclerosis,COVID-19,Infectious,N/A,4/19/21,9/6/21,4.7,41,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Novartis,INDUSTRY,"76,057",Big Pharma,FALSE,Novartis Pharmaceuticals,SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""","ModernaTX, Inc.",$141.80 
2020,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04470427,https://clinicaltrials.gov/study/NCT04470427,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,7/27/20,12/29/22,29.5,30415,ACTUAL,11,7,'1a.1. US Population'!$G$11,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",1.44%,"3,584,405",Common,67.69%,"168,658,393",0.773329128,"856,186","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority"", ""National Institute of Allergy and Infectious Diseases (NIAID)""","ModernaTX, Inc.",$141.80 
2020,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04649151,https://clinicaltrials.gov/study/NCT04649151,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/9/20,6/14/24,42.8,4331,ACTUAL,11,6,'1a.1. US Population'!$F$11,ALL,"CHILD, ADULT",COVID-19,"274,482,899",0.89%,"2,455,274",Common,41.95%,"115,145,576",0.851942052,"943,222","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04796896,https://clinicaltrials.gov/study/NCT04796896,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,3/15/21,3/15/24,36.5,11950,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"43,782,216","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04811664,https://clinicaltrials.gov/study/NCT04811664,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2 Infection,COVID-19,Infectious,N/A,3/24/21,12/30/21,9.4,1923,ACTUAL,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,67.69%,"136,367,853",0.62527118,"120,773,161",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04860297,https://clinicaltrials.gov/study/NCT04860297,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,4/16/21,5/22/23,25.5,234,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05119855,https://clinicaltrials.gov/study/NCT05119855,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,"Papillomavirus Infections, Coronavirus Disease (COVID-19)",COVID-19,Infectious,N/A,3/28/22,12/12/23,20.8,165,ACTUAL,9,3,'1a.1. US Population'!$C$9,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"12,309,808",Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05158140,https://clinicaltrials.gov/study/NCT05158140,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,Pneumococcal Infection,COVID-19,Infectious,N/A,1/12/22,2/21/23,13.5,850,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163",Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05077254,https://clinicaltrials.gov/study/NCT05077254,Interventional,Phase 2,Active Not Recruiting,TREATMENT,PREVENTION,"Kidney Transplant Recipients, Liver Transplant Recipients",COVID-19,Infectious,N/A,12/6/21,2/28/24,27.1,400,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""PPD DEVELOPMENT, LP"", ""Johns Hopkins University""","ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04847050,https://clinicaltrials.gov/study/NCT04847050,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma",COVID-19,Infectious,N/A,4/28/21,5/25/23,25.2,19,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institutes of Health Clinical Center (CC),NIH,non-industry,Non-Industry,FALSE,National Cancer Institute (NCI),PRINCIPAL_INVESTIGATOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04889209,https://clinicaltrials.gov/study/NCT04889209,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,5/28/21,6/16/23,25,867,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05137236,https://clinicaltrials.gov/study/NCT05137236,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/6/21,3/23/23,15.7,540,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05397223,https://clinicaltrials.gov/study/NCT05397223,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus",COVID-19,Infectious,N/A,5/24/22,2/21/26,45.6,308,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2020,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04283461,https://clinicaltrials.gov/study/NCT04283461,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"COVID-19, COVID-19 Immunisation",COVID-19,Infectious,N/A,3/16/20,4/26/22,25.7,120,ACTUAL,11,7,'1a.1. US Population'!$G$11,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",1.44%,"3,584,405",Common,67.69%,"168,658,393",0.773329128,"856,186",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""ModernaTX, Inc.""","ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04785144,https://clinicaltrials.gov/study/NCT04785144,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"COVID-19, COVID-19 Immunisation",COVID-19,Infectious,N/A,3/31/21,7/5/22,15.4,135,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""ModernaTX, Inc.""","ModernaTX, Inc.",$141.80 
2021,mrna-1273,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04813796,https://clinicaltrials.gov/study/NCT04813796,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,3/11/21,7/25/23,28.9,104,ACTUAL,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,67.69%,"136,367,853",0.62527118,"120,773,161","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2023,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06130345,https://clinicaltrials.gov/study/NCT06130345,Observational,Observational,Active Not Recruiting,,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,4/14/23,2/29/24,10.7,10000000,ESTIMATED,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,"3,285,137","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Aetion, Inc.""","ModernaTX, Inc.",$141.80 
2023,mrna-1273,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05765578,https://clinicaltrials.gov/study/NCT05765578,Observational,Observational,Completed,,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/8/23,6/17/24,15.6,1713,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"2,540,492","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2024,mrna-1273 variant-containing formulation,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06585241,https://clinicaltrials.gov/study/NCT06585241,Interventional,Phase 4,Recruiting,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,9/9/24,10/29/24,1.7,100,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,79.15%,"197,213,032",0.773329128,"2,540,492","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.211,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.211,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04889209,https://clinicaltrials.gov/study/NCT04889209,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,5/28/21,6/16/23,25,867,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.213,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.214,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05330975,https://clinicaltrials.gov/study/NCT05330975,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,COVID-19,Infectious,N/A,4/1/22,11/12/24,31.9,3800,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.214,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04796896,https://clinicaltrials.gov/study/NCT04796896,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,3/15/21,3/15/24,36.5,11950,ACTUAL,10,3,'1a.1. US Population'!$C$10,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"43,782,216","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.214,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.214,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05436834,https://clinicaltrials.gov/study/NCT05436834,Interventional,Phase 3,Recruiting,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,6/21/22,10/27/25,40.8,1860,ESTIMATED,9,3,'1a.1. US Population'!$C$9,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"12,309,808","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.214,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05584202,https://clinicaltrials.gov/study/NCT05584202,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,9/30/22,3/8/25,29.7,700,ESTIMATED,9,3,'1a.1. US Population'!$C$9,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"12,309,808","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.214,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05585632,https://clinicaltrials.gov/study/NCT05585632,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza, RSV",COVID-19,Infectious,N/A,10/14/22,2/28/24,16.7,392,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2023,mrna-1273.222,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05815498,https://clinicaltrials.gov/study/NCT05815498,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/28/23,4/18/25,25.1,14246,ACTUAL,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,"3,285,137","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2020,mrna-1273.222,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04649151,https://clinicaltrials.gov/study/NCT04649151,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/9/20,6/14/24,42.8,4331,ACTUAL,11,6,'1a.1. US Population'!$F$11,ALL,"CHILD, ADULT",COVID-19,"274,482,899",0.89%,"2,455,274",Common,41.95%,"115,145,576",0.851942052,"943,222","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",$141.80 
2021,mrna-1273.222,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.222,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04889209,https://clinicaltrials.gov/study/NCT04889209,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,5/28/21,6/16/23,25,867,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.231,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2020,mrna-1273.351,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04405076,https://clinicaltrials.gov/study/NCT04405076,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/29/20,10/28/21,17.2,660,ACTUAL,11,7,'1a.1. US Population'!$G$11,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",1.44%,"3,584,405",Common,67.69%,"168,658,393",0.773329128,"856,186","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",$141.80 
2022,mrna-1273.351,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.351,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04785144,https://clinicaltrials.gov/study/NCT04785144,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"COVID-19, COVID-19 Immunisation",COVID-19,Infectious,N/A,3/31/21,7/5/22,15.4,135,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""ModernaTX, Inc.""","ModernaTX, Inc.",$141.80 
2021,mrna-1273.529,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.529,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.617.2,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.617.2,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05289037,https://clinicaltrials.gov/study/NCT05289037,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/30/22,11/22/23,20.1,1270,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.65%,"208,415,212",0.773329128,"41,997,163",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,"ModernaTX, Inc.",$141.80 
2023,mrna-1273.815,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05815498,https://clinicaltrials.gov/study/NCT05815498,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/28/23,4/18/25,25.1,14246,ACTUAL,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,"3,285,137","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1273.815,Spikevax,80777-110,messenger RNA,LNP,Untargeted,in-vivo,NCT04927065,https://clinicaltrials.gov/study/NCT04927065,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,5/28/21,11/17/23,30.1,5404,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2022,mrna-1273.815,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05436834,https://clinicaltrials.gov/study/NCT05436834,Interventional,Phase 3,Recruiting,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,6/21/22,10/27/25,40.8,1860,ESTIMATED,9,3,'1a.1. US Population'!$C$9,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,41.95%,"30,636,060",0.226670872,"12,309,808","ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",$141.80 
2021,mrna-1283,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05137236,https://clinicaltrials.gov/study/NCT05137236,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/6/21,3/23/23,15.7,540,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1283,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04813796,https://clinicaltrials.gov/study/NCT04813796,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,3/11/21,7/25/23,28.9,104,ACTUAL,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1283.211,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05137236,https://clinicaltrials.gov/study/NCT05137236,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/6/21,3/23/23,15.7,540,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1283.222,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05815498,https://clinicaltrials.gov/study/NCT05815498,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/28/23,4/18/25,25.1,14246,ACTUAL,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1283.529,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05137236,https://clinicaltrials.gov/study/NCT05137236,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,SARS-CoV-2,COVID-19,Infectious,N/A,12/6/21,3/23/23,15.7,540,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1283.815,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05815498,https://clinicaltrials.gov/study/NCT05815498,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/28/23,4/18/25,25.1,14246,ACTUAL,8,8,'1a.1. US Population'!$H$8,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,46.36%,"149,359,569",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2016,mrna-1325,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT03014089,https://clinicaltrials.gov/study/NCT03014089,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,Zika Virus,Zika Virus,Infectious,N/A,12/21/16,7/31/19,31.7,90,ACTUAL,15,4,'1a.1. US Population'!$D$15,ALL,ADULT,Zika Virus,"200,063,580",0.00%,23,Ultra-Rare,67.69%,"135,427,353",0.620023687,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",N/A
2021,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05127434,https://clinicaltrials.gov/study/NCT05127434,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,11/17/21,8/25/25,45.9,36814,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,67.69%,"168,658,393",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05330975,https://clinicaltrials.gov/study/NCT05330975,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,4/1/22,11/12/24,31.9,3800,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,83.65%,"208,415,212",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06067230,https://clinicaltrials.gov/study/NCT06067230,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,10/6/23,7/30/26,34.3,1150,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06060457,https://clinicaltrials.gov/study/NCT06060457,Interventional,Phase 3,Completed,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,9/25/23,6/7/24,8.5,1900,ACTUAL,8,5,'1a.1. US Population'!$E$8,ALL,OLDER_ADULT,Respiratory Syncytial Virus,"47,702,041",0.04%,"17,548",Rare,83.19%,"39,682,064",0.148057948,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06097299,https://clinicaltrials.gov/study/NCT06097299,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,10/24/23,3/4/25,16.6,400,ESTIMATED,8,3,'1a.1. US Population'!$C$8,ALL,CHILD,Respiratory Syncytial Virus,"73,029,941",0.02%,"11,033",Rare,46.36%,"33,855,464",0.226670872,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06143046,https://clinicaltrials.gov/study/NCT06143046,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,11/15/23,2/18/26,27.5,360,ESTIMATED,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Respiratory Syncytial Virus,"201,452,958",0.04%,"74,107",Rare,83.19%,"167,583,377",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05397223,https://clinicaltrials.gov/study/NCT05397223,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus",Respiratory Syncytial Virus,Infectious,N/A,5/24/22,2/21/26,45.6,308,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,83.65%,"208,415,212",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05743881,https://clinicaltrials.gov/study/NCT05743881,Interventional,Phase 1,Active Not Recruiting,TREATMENT,TREATMENT,"Respiratory Syncytial Virus, Human Metapneumovirus",Respiratory Syncytial Virus,Infectious,N/A,2/15/23,7/30/26,42,310,ESTIMATED,8,3,'1a.1. US Population'!$C$8,ALL,CHILD,Respiratory Syncytial Virus,"73,029,941",0.02%,"11,033",Rare,100.00%,"11,033",0.226670872,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2020,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04528719,https://clinicaltrials.gov/study/NCT04528719,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,9/30/20,7/18/24,46.2,651,ACTUAL,11,8,'1a.1. US Population'!$H$11,ALL,"CHILD, ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"322,184,940",0.02%,"50,628",Rare,41.95%,"135,156,583",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05585632,https://clinicaltrials.gov/study/NCT05585632,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"SARS-CoV-2, Influenza, RSV",Respiratory Syncytial Virus,Infectious,N/A,10/14/22,2/28/24,16.7,392,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,83.65%,"208,415,212",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1345,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05572658,https://clinicaltrials.gov/study/NCT05572658,Observational,Observational,Active Not Recruiting,PREVENTION,PREVENTION,Respiratory Syncytial Virus,Respiratory Syncytial Virus,Infectious,N/A,9/15/22,6/30/26,46.1,11010,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,83.65%,"208,415,212",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1365,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05743881,https://clinicaltrials.gov/study/NCT05743881,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"Respiratory Syncytial Virus, Human Metapneumovirus",Respiratory Syncytial Virus,Infectious,N/A,2/15/23,7/30/26,42,310,ESTIMATED,8,3,'1a.1. US Population'!$C$8,ALL,CHILD,Respiratory Syncytial Virus,"73,029,941",0.02%,"11,033",Rare,46.36%,"33,855,464",0.226670872,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2024,mrna-1403,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06592794,https://clinicaltrials.gov/study/NCT06592794,Interventional,Phase 3,Recruiting,PREVENTION,PREVENTION,"Acute Gastroenteritis, Norovirus Acute Gastroenteritis",Norovirus,Infectious,N/A,9/24/24,5/31/27,32.6,25000,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Norovirus,"249,154,999",6.67%,"16,610,333",Common,79.15%,"197,213,032",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1403,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05992935,https://clinicaltrials.gov/study/NCT05992935,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Norovirus Acute Gastroenteritis,Norovirus,Infectious,N/A,8/25/23,4/14/25,19.9,1285,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Norovirus,"249,154,999",6.67%,"16,610,333",Common,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1405,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05992935,https://clinicaltrials.gov/study/NCT05992935,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Norovirus Acute Gastroenteritis,Norovirus,Infectious,N/A,8/25/23,4/14/25,19.9,1285,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Norovirus,"249,154,999",6.67%,"16,610,333",Common,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1468,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05701800,https://clinicaltrials.gov/study/NCT05701800,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,Herpes Zoster,Shingles,Infectious,N/A,1/23/23,6/30/26,41.8,657,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Shingles,"249,154,999",0.12%,"298,495",Common,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1608,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06033261,https://clinicaltrials.gov/study/NCT06033261,Interventional,Phase 2,Active Not Recruiting,TREATMENT,TREATMENT,Genital Herpes,Herpes,Infectious,N/A,9/6/23,4/11/25,19.4,365,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,Herpes,"201,452,958",36.16%,"72,853,968",Common,100.00%,"72,853,968",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05085366,https://clinicaltrials.gov/study/NCT05085366,Interventional,Phase 3,Active Not Recruiting,PREVENTION,PREVENTION,Cytomegalovirus Infection,Cytomegalovirus Infection,Infectious,N/A,10/26/21,4/6/26,54.1,7454,ACTUAL,10,18,'1a.1. US Population'!$R$10,FEMALE,"CHILD, ADULT",Cytomegalovirus Infection,"137,044,846",33.33%,"45,681,615",Common,41.95%,"57,490,313",0.425360807,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2020,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04232280,https://clinicaltrials.gov/study/NCT04232280,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Cytomegalovirus Infection,Cytomegalovirus Infection,Infectious,N/A,1/9/20,1/4/23,36.4,315,ACTUAL,11,4,'1a.1. US Population'!$D$11,ALL,ADULT,Cytomegalovirus Infection,"201,452,958",41.84%,"84,295,919",Common,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04975893,https://clinicaltrials.gov/study/NCT04975893,Interventional,Phase 2,Enrolling By Invitation,PREVENTION,PREVENTION,Cytomegalovirus Infection,Cytomegalovirus Infection,Infectious,N/A,6/18/21,12/30/26,67.4,291,ESTIMATED,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,Cytomegalovirus Infection,"201,452,958",41.84%,"84,295,919",Common,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05683457,https://clinicaltrials.gov/study/NCT05683457,Interventional,Phase 2,Recruiting,PREVENTION,PREVENTION,Cytomegalovirus Infection,Cytomegalovirus Infection,Infectious,N/A,4/5/23,8/1/25,28.3,224,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Cytomegalovirus Infection,"249,154,999",41.84%,"104,256,347",Common,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05397223,https://clinicaltrials.gov/study/NCT05397223,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus",Cytomegalovirus Infection,Infectious,N/A,5/24/22,2/21/26,45.6,308,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Cytomegalovirus Infection,"249,154,999",41.84%,"104,256,347",Common,83.65%,"208,415,212",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1647,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05105048,https://clinicaltrials.gov/study/NCT05105048,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,Cytomegalovirus Infection,Cytomegalovirus Infection,Infectious,N/A,11/8/21,8/10/23,21.3,9,ACTUAL,10,4,'1a.1. US Population'!$D$10,ALL,ADULT,Cytomegalovirus Infection,"201,452,958",41.84%,"84,295,919",Common,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-1893,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04917861,https://clinicaltrials.gov/study/NCT04917861,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Zika Virus,Zika Virus,Infectious,N/A,6/8/21,7/26/24,38.1,808,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",Zika Virus,"249,154,999",0.00%,0,Ultra-Rare,67.69%,"168,658,393",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2019,mrna-1893,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04064905,https://clinicaltrials.gov/study/NCT04064905,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,Zika Virus,Zika Virus,Infectious,N/A,7/30/19,3/22/21,20,120,ACTUAL,12,4,'1a.1. US Population'!$D$12,ALL,ADULT,Zika Virus,"201,452,958",0.00%,0,Ultra-Rare,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Biomedical Advanced Research and Development Authority""","ModernaTX, Inc.",N/A
2019,mrna-1944,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT03829384,https://clinicaltrials.gov/study/NCT03829384,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,Prevention of Chikungunya Virus Infection,Chikungunya Virus,Infectious,N/A,1/22/19,6/7/21,28.9,39,ACTUAL,12,4,'1a.1. US Population'!$D$12,ALL,ADULT,Chikungunya Virus,"201,452,958",0.00%,213,Ultra-Rare,67.69%,"136,367,853",0.62527118,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-1982,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05975099,https://clinicaltrials.gov/study/NCT05975099,Interventional,Phase 2,Active Not Recruiting,TREATMENT,PREVENTION,Lyme Disease,Lyme Disease,Infectious,N/A,7/26/23,3/12/26,32,807,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Lyme Disease,"249,154,999",0.15%,"368,105",Common,83.19%,"207,265,441",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2017,mrna-2416,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT03323398,https://clinicaltrials.gov/study/NCT03323398,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,"Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer",Cancer,Cancer,This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.,8/15/17,8/18/21,48.8,79,ACTUAL,14,7,'1a.1. US Population'!$G$14,ALL,"ADULT, OLDER_ADULT",Cancer,"250,825,102",6.98%,"17,495,640",Common,100.00%,"17,495,640",0.77283439,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2022,mrna-3745,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05095727,https://clinicaltrials.gov/study/NCT05095727,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Glycogen Storage Disease,Glycogen Storage Disease,Genetic/Inherited Metabolic,N/A,6/1/22,5/26/26,48.5,45,ESTIMATED,9,8,'1a.1. US Population'!$H$9,ALL,"CHILD, ADULT, OLDER_ADULT",Glycogen Storage Disease,"322,184,940",0.00%,"3,222",Ultra-Rare,100.00%,"3,222",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-3927,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04159103,https://clinicaltrials.gov/study/NCT04159103,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Propionic Acidemia,Propionic Acidemia,Genetic/Inherited Metabolic,N/A,4/15/21,3/5/25,47.3,68,ESTIMATED,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",Propionic Acidemia,"322,184,940",0.00%,"2,742",Ultra-Rare,100.00%,"2,742",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2021,mrna-3927,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05130437,https://clinicaltrials.gov/study/NCT05130437,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Propionic Acidemia,Propionic Acidemia,Genetic/Inherited Metabolic,N/A,11/9/21,12/4/29,98.2,36,ESTIMATED,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",Propionic Acidemia,"322,184,940",0.00%,"2,742",Ultra-Rare,100.00%,"2,742",1,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2023,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT05933577,https://clinicaltrials.gov/study/NCT05933577,Interventional,Phase 3,Active Not Recruiting,TREATMENT,TREATMENT,Melanoma,Melanoma,Cancer,N/A,7/19/23,10/26/29,76.4,1089,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Melanoma,"249,154,999",0.36%,"894,673",Common,100.00%,"894,673",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,"""ModernaTX, Inc.""",Merck Sharp & Dohme LLC,N/A
2023,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT06077760,https://clinicaltrials.gov/study/NCT06077760,Interventional,Phase 3,Recruiting,TREATMENT,TREATMENT,Non-small Cell Lung Cancer,Lung Cancer,Cancer,N/A,12/6/23,6/25/30,79.8,868,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Lung Cancer,"249,154,999",0.18%,"455,123",Common,100.00%,"455,123",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,"""ModernaTX, Inc.""",Merck Sharp & Dohme LLC,N/A
2024,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT06295809,https://clinicaltrials.gov/study/NCT06295809,Interventional,Phase 3,Recruiting,TREATMENT,TREATMENT,"Carcinoma, Squamous Cell, Skin Neoplasms",Non-melanoma skin cancer (squamous-cell carcinoma),Cancer,N/A,4/18/24,4/30/29,61.3,1012,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Non-melanoma skin cancer (squamous-cell carcinoma),"249,154,999",0.58%,"1,453,436",Common,100.00%,"1,453,436",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,"""ModernaTX, Inc.""",Merck Sharp & Dohme LLC,N/A
2024,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT06623422,https://clinicaltrials.gov/study/NCT06623422,Interventional,Phase 3,Recruiting,TREATMENT,TREATMENT,"Carcinoma, Non-Small-Cell Lung",Lung Cancer,Cancer,N/A,10/21/24,5/16/33,104.3,680,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Lung Cancer,"249,154,999",0.18%,"455,123",Common,100.00%,"455,123",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,"""ModernaTX, Inc.""",Merck Sharp & Dohme LLC,N/A
2019,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT03897881,https://clinicaltrials.gov/study/NCT03897881,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Melanoma,Melanoma,Cancer,N/A,7/18/19,9/9/29,123.5,267,ESTIMATED,12,7,'1a.1. US Population'!$G$12,ALL,"ADULT, OLDER_ADULT",Melanoma,"249,154,999",0.36%,"895,960",Common,100.00%,"895,960",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Merck Sharp & Dohme LLC""","ModernaTX, Inc.",N/A
2024,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT06307431,https://clinicaltrials.gov/study/NCT06307431,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Renal Cell Carcinoma,Kidney Cancer,Cancer,N/A,4/10/24,1/8/28,45.6,272,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Kidney Cancer,"249,154,999",0.20%,"510,559",Common,100.00%,"510,559",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,"""ModernaTX, Inc.""",Merck Sharp & Dohme LLC,N/A
2017,mrna-4157,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT03313778,https://clinicaltrials.gov/study/NCT03313778,Interventional,Phase 1,Recruiting,TREATMENT,TREATMENT,Solid Tumors,Cancer,Cancer,N/A,8/14/17,6/30/25,95.9,242,ESTIMATED,14,7,'1a.1. US Population'!$G$14,ALL,"ADULT, OLDER_ADULT",Cancer,"250,825,102",6.98%,"17,495,640",Common,100.00%,"17,495,640",0.77283439,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,"""Merck Sharp & Dohme LLC""","ModernaTX, Inc.",N/A
2022,mrna-4359,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT05533697,https://clinicaltrials.gov/study/NCT05533697,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Advanced Solid Tumors,Cancer,Cancer,N/A,8/18/22,12/8/27,64.6,194,ESTIMATED,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Cancer,"249,154,999",6.87%,"17,125,887",Common,100.00%,"17,125,887",0.773329128,0,"ModernaTX, Inc.",INDUSTRY,"5,600",Small Pharma,TRUE,"ModernaTX, Inc.",SPONSOR,INDUSTRY,N/A,"ModernaTX, Inc.",N/A
2019,mrna-5671/v941,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT03948763,https://clinicaltrials.gov/study/NCT03948763,Interventional,Phase 1,Completed,TREATMENT,TREATMENT,"Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms",Lung Cancer,Cancer,N/A,6/26/19,8/25/22,38.5,70,ACTUAL,12,7,'1a.1. US Population'!$G$12,ALL,"ADULT, OLDER_ADULT",Lung Cancer,"249,154,999",0.18%,"451,881",Common,100.00%,"451,881",0.773329128,0,Merck Sharp & Dohme LLC,INDUSTRY,"72,000",Big Pharma,TRUE,Merck Sharp & Dohme LLC,SPONSOR,INDUSTRY,N/A,Merck Sharp & Dohme LLC,N/A
2022,mrna-covid-19,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04978038,https://clinicaltrials.gov/study/NCT04978038,Interventional,Phase 4,Unknown,PREVENTION,PREVENTION,"SARS-CoV2 Infection, Coronavirus Infection",COVID-19,Infectious,N/A,8/1/22,11/15/22,3.5,414,ESTIMATED,9,5,'1a.1. US Population'!$E$9,ALL,OLDER_ADULT,COVID-19,"47,702,041",2.61%,"1,245,103",Common,83.65%,"39,902,194",0.148057948,"14,595,752",McMaster University,OTHER,non-industry,Non-Industry,FALSE,Mark Loeb,SPONSOR_INVESTIGATOR,OTHER,N/A,BioNTech SE,$136.75 
2023,mRNA-CR-04 vaccine,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT05972993,https://clinicaltrials.gov/study/NCT05972993,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,8/7/23,11/9/23,3.1,72,ACTUAL,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,COVID-19,"201,452,958",2.61%,"5,258,259",Common,83.19%,"167,583,377",0.62527118,0,GlaxoSmithKline,INDUSTRY,"3,211",Small Pharma,TRUE,GlaxoSmithKline,SPONSOR,INDUSTRY,N/A,GlaxoSmithKline,N/A
2024,mrna-np (nanoparticle) vaccine,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT05264974,https://clinicaltrials.gov/study/NCT05264974,Interventional,Phase 1,Recruiting,TREATMENT,TREATMENT,Melanoma,Melanoma,Cancer,N/A,11/1/24,9/1/26,22.3,18,ESTIMATED,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Melanoma,"249,154,999",0.36%,"894,673",Common,100.00%,"894,673",0.773329128,0,University of Florida,OTHER,non-industry,Non-Industry,TRUE,University of Florida,SPONSOR,OTHER,N/A,University of Florida,N/A
2018,NCI-4650,N/A,N/A,messenger RNA,Other,Active,in-vivo,NCT03480152,https://clinicaltrials.gov/study/NCT03480152,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,"Melanoma, Colon Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Hepatocellular Cancer",Cancer,Cancer,slow accrual,5/18/18,6/25/19,13.4,5,ACTUAL,13,7,'1a.1. US Population'!$G$13,ALL,"ADULT, OLDER_ADULT",Cancer,"252,947,586",6.89%,"17,426,568",Common,100.00%,"17,426,568",0.775154119,0,National Institutes of Health Clinical Center (CC),NIH,non-industry,Non-Industry,FALSE,National Cancer Institute (NCI),PRINCIPAL_INVESTIGATOR,NIH,N/A,National Institutes of Health Clinical Center (CC),N/A
2022,pf-07836391 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07836394 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07836395 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07836396 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07852352 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07867246 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07871987 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07914705 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2022,pf-07915048 influenza saRNA,N/A,N/A,self-amplifying RNA,Other,Untargeted,in-vivo,NCT05227001,https://clinicaltrials.gov/study/NCT05227001,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,"Influenza, Human",Influenza,Infectious,N/A,4/28/22,8/4/23,15.4,442,ACTUAL,9,4,'1a.1. US Population'!$D$9,ALL,ADULT,Influenza,"201,452,958",5.68%,"11,443,436",Common,40.00%,"80,581,183",0.62527118,0,Pfizer,INDUSTRY,"88,000",Big Pharma,TRUE,Pfizer,SPONSOR,INDUSTRY,N/A,Pfizer,N/A
2023,pfizer covid-19 mrna vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05392075,https://clinicaltrials.gov/study/NCT05392075,Observational,Observational,Completed,,PREVENTION,"COVID-19 Pneumonia, COVID-19",COVID-19,Infectious,N/A,3/15/23,3/15/23,0,100,ACTUAL,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"4,820,761",Methodist Health System,OTHER,non-industry,Non-Industry,FALSE,Methodist Health System,SPONSOR,OTHER,N/A,BioNTech SE,$136.75 
2023,pfizer covid-19 mrna vaccine (2023-2024 formula xbb containing),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06065176,https://clinicaltrials.gov/study/NCT06065176,Interventional,Phase 4,Recruiting,PREVENTION,PREVENTION,"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease",COVID-19,Infectious,N/A,11/22/23,7/30/24,8.4,1500,ESTIMATED,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,83.19%,"207,265,441",0.773329128,"4,820,761",University of Utah,OTHER,non-industry,Non-Industry,FALSE,"Sarang K. Yoon, DO, MOH",SPONSOR_INVESTIGATOR,OTHER,"""Westat"", ""Novavax""",BioNTech SE,$136.75 
2023,pfizer covid-19 vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06038617,https://clinicaltrials.gov/study/NCT06038617,Interventional,Phase 4,Recruiting,PREVENTION,PREVENTION,"Fever After Vaccination, Fever, Seizures Fever",COVID-19,Infectious,N/A,10/30/23,9/1/25,22.4,600,ESTIMATED,8,3,'1a.1. US Population'!$C$8,ALL,CHILD,COVID-19,"73,029,941",1.38%,"1,007,191",Common,46.36%,"33,855,464",0.226670872,"1,413,016",Duke University,OTHER,non-industry,Non-Industry,FALSE,Duke University,SPONSOR,OTHER,"""Kaiser Permanente"",""Columbia University"", ""Children's Hospital Medical Center, Cincinnati"", ""Centers for Disease Control and Prevention""",BioNTech SE,$136.75 
2021,pfizer vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04912700,https://clinicaltrials.gov/study/NCT04912700,Observational,Observational,Completed,,PREVENTION,Covid19,COVID-19,Infectious,N/A,6/1/21,6/7/21,0.2,11834,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",William Beaumont Hospitals,OTHER,non-industry,Non-Industry,FALSE,William Beaumont Hospitals,PRINCIPAL_INVESTIGATOR,OTHER,N/A,BioNTech SE,$136.75 
2021,pfizer-biontech covid-19 vaccine (comirnaty),Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04977479,https://clinicaltrials.gov/study/NCT04977479,Interventional,Phase 2,Completed,BASIC_SCIENCE,PREVENTION,Systemic Allergic Reaction,COVID-19,Infectious,N/A,9/8/21,6/17/22,9.4,20,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",National Institutes of Health Clinical Center (CC),NIH,non-industry,Non-Industry,FALSE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2021,"pfizer-biontech covid-19 vaccine, bivalent",Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04977479,https://clinicaltrials.gov/study/NCT04977479,Interventional,Phase 2,Completed,BASIC_SCIENCE,PREVENTION,Systemic Allergic Reaction,COVID-19,Infectious,N/A,9/8/21,6/17/22,9.4,20,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",National Institutes of Health Clinical Center (CC),NIH,non-industry,Non-Industry,FALSE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,BioNTech SE,$136.75 
2021,"pfizer-biontech covid-19 vaccine, bivalent",Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05000216,https://clinicaltrials.gov/study/NCT05000216,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)",COVID-19,Infectious,N/A,8/13/21,6/22/23,22.6,257,ACTUAL,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",COVID-19,"322,184,940",1.38%,"4,443,405",Common,41.95%,"135,156,583",1,"294,240,716",National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""Autoimmunity Centers of Excellence"", ""Rho Federal Systems Division, Inc.""",BioNTech SE,$136.75 
2016,pp65-flLAMP mRNA DC,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT02465268,https://clinicaltrials.gov/study/NCT02465268,Interventional,Phase 2,Completed,TREATMENT,TREATMENT,"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM",Brain and central nervous system cancer,Cancer,N/A,8/9/16,11/30/23,89,175,ACTUAL,15,7,'1a.1. US Population'!$G$15,ALL,"ADULT, OLDER_ADULT",Brain and central nervous system cancer,"248,678,630",0.04%,"110,960",Rare,100.00%,"110,960",0.770688205,0,University of Florida,OTHER,non-industry,Non-Industry,TRUE,University of Florida,SPONSOR,OTHER,"""National Cancer Institute (NCI)""",University of Florida,N/A
2021,pp65-flLAMP mRNA DC,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT04573140,https://clinicaltrials.gov/study/NCT04573140,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,"Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma",Brain and central nervous system cancer,Cancer,N/A,10/26/21,7/31/29,94.5,52,ESTIMATED,10,8,'1a.1. US Population'!$H$10,ALL,"CHILD, ADULT, OLDER_ADULT",Brain and central nervous system cancer,"322,184,940",0.03%,"93,328",Rare,100.00%,"93,328",1,0,University of Florida,OTHER,non-industry,Non-Industry,TRUE,University of Florida,SPONSOR,OTHER,"""Pacific Pediatric Neuro-Oncology Consortium"", ""University of California, San Francisco"", ""CureSearch"", ""Team Jack Foundation"", ""Florida Department of Health"", ""Food and Drug Administration (FDA)""",University of Florida,N/A
2015,pp65-LAMP mRNA DC,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT02366728,https://clinicaltrials.gov/study/NCT02366728,Interventional,Phase 2,Completed,TREATMENT,TREATMENT,"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme",Brain and central nervous system cancer,Cancer,N/A,10/12/15,10/31/20,61.5,64,ACTUAL,16,7,'1a.1. US Population'!$G$16,ALL,"ADULT, OLDER_ADULT",Brain and central nervous system cancer,"246,502,578",0.04%,"108,466",Rare,100.00%,"108,466",0.768771744,0,Duke University,OTHER,non-industry,Non-Industry,FALSE,"Mustafa Khasraw, MBChB, MD, FRCP, FRACP",SPONSOR_INVESTIGATOR,OTHER,N/A,Duke University,N/A
2019,pp65-LAMP mRNA DC,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT03927222,https://clinicaltrials.gov/study/NCT03927222,Interventional,Phase 2,Terminated,TREATMENT,TREATMENT,Glioblastoma,Brain and central nervous system cancer,Cancer,Resource shortage,9/30/19,2/10/23,41,6,ACTUAL,12,7,'1a.1. US Population'!$G$12,ALL,"ADULT, OLDER_ADULT",Brain and central nervous system cancer,"249,154,999",0.04%,"106,930",Rare,100.00%,"106,930",0.773329128,0,Duke University,OTHER,non-industry,Non-Industry,FALSE,"Mustafa Khasraw, MBChB, MD, FRCP, FRACP",SPONSOR_INVESTIGATOR,OTHER,N/A,Duke University,N/A
2016,pp65-shLAMP mRNA DC,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT02465268,https://clinicaltrials.gov/study/NCT02465268,Interventional,Phase 2,Completed,TREATMENT,TREATMENT,"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM",Brain and central nervous system cancer,Cancer,N/A,8/9/16,11/30/23,89,175,ACTUAL,15,7,'1a.1. US Population'!$G$15,ALL,"ADULT, OLDER_ADULT",Brain and central nervous system cancer,"248,678,630",0.04%,"110,960",Rare,100.00%,"110,960",0.770688205,0,University of Florida,OTHER,non-industry,Non-Industry,TRUE,University of Florida,SPONSOR,OTHER,"""National Cancer Institute (NCI)""",University of Florida,N/A
2022,quadrivalent influenza mrna vaccine mrt5407,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT05553301,https://clinicaltrials.gov/study/NCT05553301,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,10/3/22,1/19/24,15.8,560,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2022,quadrivalent influenza mrna vaccine mrt5410,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT05624606,https://clinicaltrials.gov/study/NCT05624606,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,11/28/22,3/28/24,16.2,682,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2022,quadrivalent influenza mrna vaccine mrt5413,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT05650554,https://clinicaltrials.gov/study/NCT05650554,Interventional,Phase 2,Completed,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,12/12/22,4/2/24,15.9,682,ACTUAL,9,7,'1a.1. US Population'!$G$9,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,40.00%,"99,662,000",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,quadrivalent influenza mrna vaccine mrt5421,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06361875,https://clinicaltrials.gov/study/NCT06361875,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,4/1/24,5/22/25,13.9,910,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,quadrivalent influenza mrna vaccine mrt5424,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06361875,https://clinicaltrials.gov/study/NCT06361875,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,4/1/24,5/22/25,13.9,910,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,quadrivalent influenza mrna vaccine mrt5429,N/A,N/A,messenger RNA,unclear,Untargeted,in-vivo,NCT06361875,https://clinicaltrials.gov/study/NCT06361875,Interventional,Phase 2,Active Not Recruiting,PREVENTION,PREVENTION,Influenza Immunization,Influenza,Infectious,N/A,4/1/24,5/22/25,13.9,910,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Influenza,"249,154,999",5.68%,"14,153,126",Common,37.00%,"92,187,350",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,rsv mrna lnp 1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237296,https://clinicaltrials.gov/study/NCT06237296,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"Respiratory Syncytial Virus, Healthy Volunteers, Metapneumovirus Infection",Respiratory Syncytial Virus,Infectious,N/A,1/23/24,2/18/25,13.1,558,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,79.15%,"197,213,032",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,rsv/hmpv mrna lnp 1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237296,https://clinicaltrials.gov/study/NCT06237296,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"Respiratory Syncytial Virus, Healthy Volunteers, Metapneumovirus Infection",Respiratory Syncytial Virus,Infectious,N/A,1/23/24,2/18/25,13.1,558,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,79.15%,"197,213,032",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2024,rsv/hmpv mrna lnp 2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT06237296,https://clinicaltrials.gov/study/NCT06237296,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,"Respiratory Syncytial Virus, Healthy Volunteers, Metapneumovirus Infection",Respiratory Syncytial Virus,Infectious,N/A,1/23/24,2/18/25,13.1,558,ACTUAL,7,7,'1a.1. US Population'!$G$7,ALL,"ADULT, OLDER_ADULT",Respiratory Syncytial Virus,"249,154,999",0.04%,"91,655",Rare,79.15%,"197,213,032",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,"Sanofi Pasteur, a Sanofi Company",N/A
2021,sam-lnp-s,N/A,N/A,self-amplifying RNA,LNP,Untargeted,in-vivo,NCT04776317,https://clinicaltrials.gov/study/NCT04776317,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/18/21,9/15/23,30.4,81,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""Gritstone bio, Inc.""","Gritstone bio, Inc.",N/A
2021,sam-lnp-s-tce,N/A,N/A,self-amplifying RNA,LNP,Untargeted,in-vivo,NCT04776317,https://clinicaltrials.gov/study/NCT04776317,Interventional,Phase 1,Completed,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,N/A,3/18/21,9/15/23,30.4,81,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,"""Gritstone bio, Inc.""","Gritstone bio, Inc.",N/A
2021,sars-cov-2 mrna vaccine formulation 1,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04798027,https://clinicaltrials.gov/study/NCT04798027,Interventional,Phase 2,Terminated,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,Sponsor's decision not to pursue further development of this product given the wide availability of authorized/approved mRNA COVID-19 vaccines,3/12/21,6/27/22,15.7,182,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,Translate Bio,N/A
2021,sars-cov-2 mrna vaccine formulation 2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04798027,https://clinicaltrials.gov/study/NCT04798027,Interventional,Phase 2,Terminated,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,Sponsor's decision not to pursue further development of this product given the wide availability of authorized/approved mRNA COVID-19 vaccines,3/12/21,6/27/22,15.7,182,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,Translate Bio,N/A
2021,sars-cov-2 mrna vaccine formulation 3,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04798027,https://clinicaltrials.gov/study/NCT04798027,Interventional,Phase 2,Terminated,PREVENTION,PREVENTION,COVID-19,COVID-19,Infectious,Sponsor's decision not to pursue further development of this product given the wide availability of authorized/approved mRNA COVID-19 vaccines,3/12/21,6/27/22,15.7,182,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,0,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,"86,088",Big Pharma,TRUE,"Sanofi Pasteur, a Sanofi Company",SPONSOR,INDUSTRY,N/A,Translate Bio,N/A
2021,spikevax bivalent original/omicron ba.1,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""","ModernaTX, Inc.",$141.80 
2021,spikevax bivalent original/omicron ba.4-5,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""","ModernaTX, Inc.",$141.80 
2021,spikevax omicron xbb.1.5,Spikevax,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05075538,https://clinicaltrials.gov/study/NCT05075538,Interventional,Phase 4,Terminated,PREVENTION,PREVENTION,Cancer,COVID-19,Infectious,The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years,12/1/21,1/8/24,25.6,152,ACTUAL,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"149,371,035",Jules Bordet Institute,OTHER,non-industry,Non-Industry,FALSE,Jules Bordet Institute,SPONSOR,OTHER,"""Roche Pharma AG""","ModernaTX, Inc.",$141.80 
2021,the pfizer mrna-based bnt162b2 vaccine,Comirnaty,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT04961229,https://clinicaltrials.gov/study/NCT04961229,Interventional,Phase 4,Unknown,PREVENTION,PREVENTION,"COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression",COVID-19,Infectious,N/A,10/1/21,2/1/22,4.1,504,ESTIMATED,10,7,'1a.1. US Population'!$G$10,ALL,"ADULT, OLDER_ADULT",COVID-19,"249,154,999",2.61%,"6,503,362",Common,67.69%,"168,658,393",0.773329128,"227,544,916",Rabin Medical Center,OTHER,non-industry,Non-Industry,FALSE,dafna yahav,SPONSOR_INVESTIGATOR,OTHER,N/A,BioNTech SE,$136.75 
2021,TTMA-xALT,N/A,N/A,messenger RNA,Other,Active,ex-vivo,NCT04837547,https://clinicaltrials.gov/study/NCT04837547,Interventional,Phase 1,Recruiting,TREATMENT,TREATMENT,"Neuroblastoma, Diffuse Intrinsic Pontine Glioma",Neuroblastoma,Genetic/Inherited Metabolic,N/A,9/20/21,9/1/25,48.1,24,ESTIMATED,10,6,'1a.1. US Population'!$F$10,ALL,"CHILD, ADULT",Neuroblastoma,"274,482,899",0.01%,"16,563",Rare,100.00%,"16,563",0.851942052,0,University of Florida,OTHER,non-industry,Non-Industry,TRUE,N/A,N/A,N/A,"""Beat Childhood Cancer Research Consortium""",University of Florida,N/A
2023,V3G CH848 mRNA-Tr2,N/A,N/A,messenger RNA,LNP,Untargeted,in-vivo,NCT05903339,https://clinicaltrials.gov/study/NCT05903339,Interventional,Phase 1,Active Not Recruiting,PREVENTION,PREVENTION,HIV,HIV,Infectious,N/A,8/29/23,8/30/25,24.4,36,,8,4,'1a.1. US Population'!$D$8,ALL,ADULT,HIV,"201,452,958",1.21%,"2,440,835",Common,83.19%,"167,583,377",0.62527118,0,National Institute of Allergy and Infectious Diseases (NIAID),NIH,non-industry,Non-Industry,TRUE,National Institute of Allergy and Infectious Diseases (NIAID),SPONSOR,NIH,N/A,Duke Human Vaccine Institute,N/A
2019,vrp-her2,N/A,N/A,self-amplifying RNA,Other,Active,in-vivo,NCT03632941,https://clinicaltrials.gov/study/NCT03632941,Interventional,Phase 2,Active Not Recruiting,TREATMENT,TREATMENT,"Breast Cancer, HER2+ Breast Cancer",Breast Cancer,Cancer,N/A,3/1/19,10/3/23,55.9,9,ACTUAL,12,7,'1a.1. US Population'!$G$12,ALL,"ADULT, OLDER_ADULT",Breast Cancer,"249,154,999",1.49%,"3,720,434",Common,100.00%,"3,720,434",0.773329128,0,Duke University,OTHER,non-industry,Non-Industry,FALSE,Herbert Lyerly,SPONSOR_INVESTIGATOR,OTHER,"""Merck Sharp & Dohme LLC""",Duke University,N/A
2023,VX-522,N/A,N/A,messenger RNA,LNP,Active,in-vivo,NCT05668741,https://clinicaltrials.gov/study/NCT05668741,Interventional,Phase 2,Recruiting,TREATMENT,TREATMENT,Cystic Fibrosis,Cystic Fibrosis,Genetic/Inherited Metabolic,N/A,2/27/23,3/1/25,24.4,33,,8,7,'1a.1. US Population'!$G$8,ALL,"ADULT, OLDER_ADULT",Cystic Fibrosis,"249,154,999",0.01%,"30,933",Rare,100.00%,"30,933",0.773329128,0,Vertex Pharmaceuticals Incorporated,INDUSTRY,"5,400",Small Pharma,FALSE,Vertex Pharmaceuticals Incorporated,SPONSOR,INDUSTRY,"""Moderna, Inc""","ModernaTX, Inc.",N/A